Why am I not losing weight on tirzepatide or semaglutide?
In US label trials, 9 to 15 in 100 people on tirzepatide (Mounjaro, Zepbound) lost under 5% of their weight. About 17 in 100 on semaglutide 2.4 mg (Wegovy) did too. More did with type 2 diabetes. Starting doses are not maintenance doses, so early results can mislead.
How many people lose little on these medicines?
In US label trials, 9 to 15 in 100 people on tirzepatide and about 17 in 100 on semaglutide 2.4 mg lost under 5%.1,2
In the main US Zepbound trial, in adults without diabetes, 85.1% to 90.9% lost at least 5% over 72 weeks. On a placebo (dummy injection), 34.5% did.1 In the main US Wegovy trial, 83.5% reached 5% over 68 weeks, against 31.1% on placebo.2 For a 100 kg person, 5% is 5 kg.
Everyone in these trials also had diet and activity advice. In the Zepbound trials, that meant about 500 fewer calories a day and at least 150 minutes of activity a week.1
Type 2 diabetes changes the numbers. With diabetes, 79.2% to 82.8% on Zepbound and 67.4% on Wegovy reached 5%. Average loss was 12.8% to 14.7% on Zepbound and 9.6% on Wegovy.1,2
Could it be too early, or the dose?
It can be, because both medicines start low and step up over months, and the first dose is not meant as a dose to stay on.1,2
- Tirzepatide: the US Zepbound label starts at 2.5 mg for 4 weeks, which is “not approved as a maintenance dosage.” The dose can then rise in 2.5 mg steps, after at least 4 weeks on each, to 15 mg at most. Blood levels settle after 4 weeks on a dose.1
- Semaglutide: the US Wegovy injection starts at 0.25 mg and steps up every 4 weeks, reaching its 2.4 mg maintenance dose at week 17. Its half-life (the time for half to leave the body) is about 1 week.2
NIH says most weight loss takes place within the first 6 months of starting the medication.7
Missed doses can matter too. The US Zepbound label says to take a missed dose within 4 days, or skip it and keep to the usual day.1 The US Wegovy label says that after 2 or more missed doses in a row, the step-up restarts at a lower dose.2
The EU, UK, Canadian and Australian tirzepatide labels we checked also start at 2.5 mg.3,4,5,6
In the Zepbound trial, average loss rose with dose: 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg.1 Stopping because of side effects also rose, from 4.8% on 5 mg to 6.7% on 15 mg, against 3.4% on placebo. Nausea affected 25 to 29 in 100 on Zepbound, against 8 on placebo.1 On Wegovy 2.4 mg it was 44 in 100, against 16.2
What can a prescriber check or change?
The US health agency NIH says your clinician will probably advise stopping if you lose under 5% after 12 weeks on the full dose.7
NIH adds that a clinician may instead change the plan or try a different medicine.7
- Other medicines and conditions: NIH links some medicines for epilepsy, depression or psychotic disorders to weight gain. It also names steroids, insulin and sulfonylureas, and some blood pressure medicines. Health problems on its list include polycystic ovary syndrome (PCOS), Cushing’s syndrome, an underactive thyroid (hypothyroidism) and too little sleep.8
- A higher dose: both US labels say to weigh “treatment response and tolerability” when choosing a maintenance dose. The US Wegovy label allows 7.2 mg after at least 4 weeks on 2.4 mg, if more loss is “clinically indicated.”1,2
- A different medicine: in SURMOUNT-5, 751 adults without diabetes were randomly assigned to one medicine or the other. Average loss at 72 weeks was 20.2% on tirzepatide and 13.7% on semaglutide. The trial was funded by Eli Lilly, and it did not test switching after a poor response.9 Our side effects guide covers the risks.
What do people on GLP-1 medicines report when they don’t lose weight?
From public patient forums: 3,797 Reddit threads in r/Zepbound, r/Mounjaro, r/WegovyWeightLoss, r/Semaglutide, r/mounjarouk and r/Ozempic, read from October 2025 to October 2026. Personal reports, not medical evidence.
What people describe
- Matches the label Many say they felt no change, or lost little, on the first doses. The US Zepbound label calls 2.5 mg a starting dose, and Wegovy reaches its maintenance dose at week 17.1,2
- Matches NIH Several blame PCOS, an underactive thyroid or another health condition. NIH lists PCOS and hypothyroidism among health problems that may lead to weight gain.8
- Matches the label A few with type 2 diabetes say they lose more slowly. In the US Wegovy trials, average loss was 9.6% with diabetes and 14.9% without.2
- Not studied Several say switching medicine changed their results. More found the new medicine weaker than found it helped, though most of those it helped had moved from semaglutide to tirzepatide. We found no randomised trial of switching after a poor response.
Advice people share
- Matches the label Many advise judging the medicine only after reaching the top dose you tolerate, with the prescriber. Both US labels say to weigh response and tolerability when choosing a maintenance dose.1,2
- Matches the label Many say the medicine makes eating less easier but doesn’t replace it, and suggest logging food for a while. Both US labels pair the medicine with a reduced-calorie diet and more activity.1,2
- Label says otherwise A few suggest a new injection site to restore the effect, and others disagree. Both US labels report similar exposure from the abdomen, thigh or upper arm.1,2
- Label says otherwise Several describe counting pen clicks for in-between doses, splitting doses or changing the weekly gap. The UK Mounjaro KwikPen SmPC says each pen contains 4 doses, and any solution left after use should be discarded. The US labels set one injection a week, and Zepbound rises only in 2.5 mg steps.4,1,2
In your country
The trial numbers above come from US labels, the other labels we opened start tirzepatide the same way, and the UK adds a formal 5% check.
Australia
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.
Label: The answer above applies.
Emergency number: 000
Canada
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.
Label: The answer above applies.
Emergency number: 911
France
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).
Label: The answer above applies.
Emergency number: 15 or 112
Germany
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.
Label: The answer above applies.
Emergency number: 112
India
Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).
Label: We could not open an Indian label for this page, so this answer relies on the US labels and EU product summaries.1,2,3,10
Emergency number: 112
Saudi Arabia
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.
Label: We could not open a Saudi label for this page, so this answer relies on the US labels and EU product summaries.1,2,3,10
Emergency number: 997 or 911
United Arab Emirates
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.
Label: We could not open a UAE label for this page, so this answer relies on the US labels and EU product summaries.1,2,3,10
Emergency number: 998 for an ambulance, or 999
United Kingdom
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.
Label: The UK SmPCs add a 5% check for weight management. On Mounjaro, it comes 6 months after reaching the highest tolerated dose. On Wegovy, it comes after 6 months of treatment. Anyone who has not lost at least 5% of their starting weight by then needs a decision on continuing.4,11
Emergency number: 999
United States
Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).
Label: The answer above applies.
Emergency number: 911
Contact your prescriber or a doctor right away if you have severe stomach pain that will not go away, with or without vomiting, sometimes felt in your back. The US Zepbound label lists it as a sign of pancreatitis (an inflamed pancreas).1
Read the full picture
Related questions
Sources
- US Zepbound (tirzepatide) prescribing information and Medication Guide, Eli Lilly (sections 1, 2.1, 2.2, 2.3, 6.1 Table 1, 12.3, 14.1 Table 2). uspl.lilly.com
- US Wegovy (semaglutide) prescribing information, Novo Nordisk, on DailyMed (sections 2.1, 2.2 Table 1, 2.4, 6.1 Table 3, 12.3, 14 Table 8). dailymed.nlm.nih.gov
- EU Mounjaro (tirzepatide) product information (SmPC sections 4.2 and 5.2), European Medicines Agency. ema.europa.eu
- UK Mounjaro KwikPen (tirzepatide) SmPC, sections 4.2 and 6.6, electronic Medicines Compendium. medicines.org.uk
- Canadian Zepbound (tirzepatide injection) Product Monograph, Health Canada Drug Product Database. pdf.hres.ca
- Australian Mounjaro (tirzepatide) Product Information, section 4.2. medsinfo.com.au
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, part of NIH). Prescription medications to treat overweight and obesity. niddk.nih.gov
- NIDDK (NIH). Factors affecting weight and health. niddk.nih.gov
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025;393:26–36. Funded by Eli Lilly. PMID 40353578. pubmed.ncbi.nlm.nih.gov
- EU Wegovy (semaglutide) product information (SmPC), European Medicines Agency. ema.europa.eu
- UK Wegovy 2.4 mg FlexTouch (semaglutide) SmPC, section 4.2, electronic Medicines Compendium. medicines.org.uk
- American College of Emergency Physicians. Know When to Go to the ER. emergencyphysicians.org
Last checked Nov 15, 2026 · Next review due Nov 15, 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on Nov 15, 2026. The “in 100” figures for people who lost under 5% are our arithmetic from the label tables. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write